Novamed, Sanofi cite Eurofarma entry in Brazilian review of Medley deal
By Maria Júlia Baumert ( October 5, 2026, 19:04 GMT | Insight) -- Novamed and Sanofi have cited Eurofarma’s recent registration of a naratriptan drug and growing use of clomiphene citrate to treat male hypogonadism in response to the Brazilian competition authority’s decision to deepen its review of Novamed’s proposed acquisition of Medley.Novamed and Sanofi have cited Eurofarma’s recent registration of a naratriptan drug and growing use of clomiphene citrate to treat male hypogonadism in response to the Brazilian competition authority’s decision to deepen its review of Novamed’s proposed acquisition of Medley. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.